Trial reportMedical science monitor : international medical journal of experimental and clinical research2016
Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.Frontiers in medicine · 2020Pooled it
- Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial.Journal of clinical pharmacology · 2021Trial
- Revolutionizing rheumatoid arthritis therapy: harnessing cytomembrane biomimetic nanoparticles for novel treatment strategies.Drug delivery and translational research · 2025Review
- Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target.Frontiers in oncology · 2024Review
- Xiaoyao-Qingluoyin Cure Adjuvant-Induced Arthritis by Easing LPS Response-Related Pathway-Mediated Immune Abnormality.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients.Frontiers in oncology · 2022Article
- Research progress on Th17 and T regulatory cells and their cytokines in regulating atherosclerosis.Frontiers in cardiovascular medicine · 2022Review
- T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives.Brain, behavior, & immunity - health · 2021Article
- Dysfunctions, Molecular Mechanisms, and Therapeutic Strategies of Regulatory T Cells in Rheumatoid Arthritis.Frontiers in pharmacology · 2021Review
- Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells.Frontiers in immunology · 2021Review
- Present Status and Future Trends of Natural-Derived Compounds Targeting T Helper (Th) 17 and Microsomal Prostaglandin E Synthase-1 (mPGES-1) as Alternative Therapies for Autoimmune and Inflammatory-Based Diseases.Molecules (Basel, Switzerland) · 2020Review
- The Balance of Th17 versus Treg Cells in Autoimmunity.International journal of molecular sciences · 2018Review
- Anti-Inflammatory Effects of p-Coumaric Acid, a Natural Compound ofEvidence-based complementary and alternative medicine : eCAM · 2018Article
- Anti-Inflammatory Effects of HDL in Mice With Rheumatoid Arthritis Induced by Collagen.Frontiers in immunology · 2018Article
- Leptin-induced migration and angiogenesis in rheumatoid arthritis is mediated by reactive oxygen species.FEBS open bio · 2017Article
- PTEN drives Th17 cell differentiation by preventing IL-2 production.The Journal of experimental medicine · 2017Article
- Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.Molecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to investigate the protective effect of interleukin-6 (IL-6) receptor antagonist tocilizumab (TCZ) on rheumatoid arthritis (RA) and its related mechanism. MATERIAL AND METHODS Thirty RA patients receiving long-term methotrexate therapy at moderate and severe active stages were selected and treated with TCZ 8 mg/kg/time iv gtt intravenously guttae every 4 weeks. Peripheral blood was extracted before and 24 weeks after TCZ treatment. Peripheral blood mononuclear cells (PBMC) were collected by density gradient centrifugation. Flow cytometry was used to detect the ratio of CD4 naïve T cells and CD4 memory T cells, Th17 cells, and Treg cells in PBMC. DAS28 score, CRP, RF, and CCP levels in patients were evaluated. RESULTS Compared with before treatment, IL-6 receptor antagonist TCZ significantly improved patients' condition, including DAS28 score, CRP, RF, and CCP levels (P<0.01). Furthermore, TCZ obviously upregulated CD4 naïve T cells proportion and decreased CD4 memory T cells ratio (P<0.01). TCZ also markedly reduced the proportion of Th17 cells and increased the proportion of Treg cells (P<0.01). CONCLUSIONS TCZ can treat RA patients through regulating the ratio of CD4 naïve T cells, CD4 memory T cells, Th17 cells, and Treg cells in PBMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.